With a late-stage win in hand, Sweden’s Hansa Biopharma is one step closer to bringing its kidney transplant drug to the U.S. Thursday, the company reported positive top-line results from a U.S. phase ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback